Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study.
Anne-Laure SennesaelAnne-Sophie LarockJonathan DouxfilsLaure ElensGabriel StillemansMartin WiesenMax TaubertJean-Michel DognéAnne SpinewineFrançois MullierPublished in: Thrombosis journal (2018)
Rivaroxaban patients admitted to the ED for bleeding events showed highly variable plasma concentrations. This analysis underlines the usefulness of rapid DOAC measurement and the value of PopPK models to estimate concentrations at trough in a context where the post-intake delay is unmanageable. Close patient follow-up, including renal function assessment and drug interactions review, is essential for bleeding risk minimization.